The bisphosphonates and denosumab are bone-modifying agents (BMAs) that reduce the risk of skeletal-related events (SREs), including fracture, need for surgery or radiotherapy to bone, spinal cord compression, and hypercalcemia of malignant neoplasm. Clinical care guidelines recommend use of BMAs in the management of metastatic bone disease (MBD).
1,2 These BMAs reduce SREs by 25% to 50%
3; however, SREs continue to occur in approximately 15% to 29% of treated patients.
1 Use of BMAs are also associated with risk of osteonecrosis of the jaw (ONJ). Based on case reports and small cohort studies, the risk of ONJ in MBD ranges from 1% to 15%.
4 The etiology of ONJ remains undefined.